GLP-1
Glucagon-like peptide-1 (7-36 amide)
30 Amino Acids · MW: 3297 Da
Amino Acids
30
Molecular Weight
3297 Da
Half-life
1-2 minutes
Research Score
4.7
Studies
1200
Storage
Store lyophilized at -20°C, reconstituted at 2-8°C
What is GLP-1?
The endogenous incretin peptide that inspired the modern GLP-1 drug class. It improves glucose-dependent insulin secretion and directly supports beta-cell survival under metabolic stress.
Key Benefits & Mechanisms
beta-cell protection
improved insulin secretion
slower gastric emptying
lower postprandial glucose
Research Summary
Native GLP-1 has a very short half-life because of rapid DPP-4 cleavage, so it is mainly used as a mechanistic research peptide. Across animal and cellular studies it reduces beta-cell apoptosis, improves insulin gene expression, and enhances islet resilience.
Related Peptides
Insulin Lispro
Insulin lispro (B28-Lys, B29-Pro human insulin analog)
A rapid-acting insulin analog with a reversed B28/B29 sequence that speeds absorption after subcutaneous injection. It is used to reduce postprandial hyperglycemia and to support flexible mealtime insulin strategies.
Diabetes & MetabolicInsulin Aspart
Insulin aspart (B28-Asp human insulin analog)
A rapid-acting insulin analog with an amino-acid substitution at B28 that promotes faster absorption after injection. It is widely used to blunt postprandial glucose excursions in diabetes research and clinical practice.
Diabetes & MetabolicInsulin Glargine
Insulin glargine (A21Gly,B31Arg,B32Arg human insulin analog)
A long-acting basal insulin analog engineered for slow release from the subcutaneous depot. It provides relatively flat day-long insulin coverage and is used to control fasting glucose.
Diabetes & MetabolicInsulin Degludec
Insulin degludec (desB30, acylated ultra-long-acting insulin analog)
An ultra-long-acting insulin analog designed with a fatty-acid side chain to form a slow-release depot. It is valued for very flat pharmacokinetics and flexible once-daily basal dosing.
Diabetes & Metabolic